Urinary Albumin Secretion in Type 2 Diabetes Patients (T2DM) with Albuminuria Treated with Sitagliptin as Add-on Therapy to Metformin: A Real-World Data Study

被引：0
|
作者：
Karasik, Avraham
Cohen, Cheli Meltzer
Chodik, Gabriel
Radican, Larry
Yu, Shengsheng
Voss, Bernd
Sharon, Offer
Gadir, Noga
Brodovicz, Kimberley
Shalev, Varda
Katzeff, Harvey
Tunceli, Kaan
机构：
来源：
DIABETES | 2014年 / 63卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1061-P
引用
收藏
页码：A275 / A275
页数：1
相关论文
共 50 条
  • [1] Urinary Albumin Secretion in Type 2 Diabetes Patients (T2DM) with Albuminuria Treated with Sitagliptin as Add-On Therapy to Metformin: A Real-World Data Study
    Cohen, Cheli Melzer
    Chodick, Gabriel
    Karasik, Avraham
    Radican, Larry
    Yu, Shengsheng
    Voss, Bernd
    Sharon, Offer
    Gadir, Noga
    Brodovicz, Kimberley
    Shalev, Varda
    Katzeff, Harvey
    Tunceli, Kaan
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 : 256 - 256
  • [2] Urinary Albumin Excretion with Sitagliptin Compared with Sulfonylurea (su) as Add-on to Metformin in Patients with Type 2 Diabetes and Albuminuria: A Real-World Evidence Study
    Karasik, Avraham
    Goldshtein, Inbal
    Chodik, Gabriel
    Katzeff, Harvey
    Radican, Larry
    Shalev, Varda
    Gadir, Noga
    Yu, Shengsheng
    Engel, Samuel
    Ommen, Elizabeth S.
    Sharon, Ofer
    Tunceli, Kaan
    DIABETES, 2015, 64 : A663 - A663
  • [3] Urinary albumin excretion with sitagliptin compared to sulfonylurea as add on to metformin in type 2 diabetes patients with albuminuria: A real-world evidence study
    Goldshtein, Inbal
    Karasik, Avraham
    Melzer-Cohen, Cheli
    Engel, Samuel S.
    Yu, Shengsheng
    Sharon, Ofer
    Brodovicz, Kimberly
    Gadir, Noga
    Katzeff, Harvey L.
    Radican, Larry
    Chodick, Gabriel
    Shalev, Varda
    Tunceli, Kaan
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2016, 30 (07) : 1354 - 1359
  • [4] Urinary albumin excretion with sitagliptin compared to sulfonylurea as add on tometformin in patients with type 2 diabetes and albuminuria: a real-world evidence study
    Katzeff, H. L.
    Goldshtein, I.
    Tunceli, K.
    Chodik, G.
    Radican, L.
    Shalev, V.
    Gadir, N.
    Yu, S.
    Engel, S. S.
    Ommen, E. S.
    Sharon, O.
    Karasik, A.
    DIABETOLOGIA, 2015, 58 : S532 - S532
  • [5] Real-World Effectiveness of Sitagliptin as Add-On Therapy in Patients With Type 2 Diabetes Mellitus
    Chen, Tse-Ying
    Hsieh, Ching-Jung
    POSTGRADUATE MEDICINE, 2014, 126 (03) : 205 - 215
  • [6] ASSESSING ADHERENCE TO SGLT2 INHIBITOR ADD-ON TO METFORMIN THERAPY IN CHINESE T2DM PATIENTS: A REAL-WORLD RETROSPECTIVE COHORT STUDY
    Bao, H.
    Jian, Y.
    Peng, X.
    Xuan, J.
    VALUE IN HEALTH, 2024, 27 (06) : S308 - S308
  • [7] Empagliflozin (EMPA) for ≥76 Weeks as Add-on to Metformin in Patients with Type 2 Diabetes (T2DM)
    Merker, Ludwig
    Haering, Hans-Ulrich
    Christiansen, Anita Vedel
    Roux, Flavien
    Salsali, Afshin
    Kim, Gabriel
    Meinicke, Thomas
    Woerle, Hans J.
    Broedl, Uli C.
    DIABETES, 2014, 63 : A278 - A278
  • [8] Empagliflozin (EMPA) for ≥76 Weeks As Add-on to Metformin in Patients with Type 2 Diabetes (T2DM)
    Merker, Ludwig
    Haering, Hans-Ulrich
    Christiansen, Anita Vedel
    Roux, Flavien
    Salsali, Afshin
    Kim, Gabriel
    Meinicke, Thomas
    Woerle, Hans-Juergen
    Broedl, Uli C.
    ENDOCRINE REVIEWS, 2014, 35 (03)
  • [9] Vildagliptin as add-on to insulin in patients with type 2 diabetes (T2DM)
    Fonseca, Vivian
    Dejager, Sylvie
    Albrecht, Diego
    Shirt, Lynda
    Schweizer, Anja
    DIABETES, 2006, 55 : A111 - A111
  • [10] Ramate as add-on to metformin (MET) in obese subjects with type 2 diabetes (T2DM)
    Toplak, H
    Vercruysse, F
    Sun, X
    Fitchet, M
    INTERNATIONAL JOURNAL OF OBESITY, 2004, 28 : S159 - S159
12345